Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Therapeutic Proteins Market Growth Performance Trended Historically, And What Lies Ahead?

The market for therapeutic proteins has seen a fast-paced growth in the past few years. The market size is poised to increase from $140.96 billion in 2024 to $158.16 billion in 2025, representing a compound annual growth rate (CAGR) of 12.2%. This impressive growth during the historic period can largely be credited to improvements in protein engineering, the proliferation into chronic disease areas, the emergence of immunotherapy, advancements in recombinant DNA technology, and the advent of targeted cancer treatments.

What Is the Forecast for the Therapeutic Proteins Market Size Through 2029?

It is anticipated that the market size of therapeutic proteins will witness accelerated expansion in the coming years, increasing to $257.4 billion in 2029 with a compound annual growth rate (CAGR) of 12.9%. The projected growth in the forecasted period could be due to regulatory adjustments, advanced delivery systems, the inclusion of gene editing, the evolution of immunotherapy, and the progress of biobetters. Key trends for the predicted period comprise enhancements in the regulatory structure, refined delivery systems, advancements in biotechnology, the rise of personalized medicine, and the prevalence of monoclonal antibodies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2555&type=smp

What are the Key Market Players in Therapeutic Proteins Market and How They’re Evolving?

Major companies operating in the therapeutic proteins market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A, Bristol Myers Squibb Co., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring LLC, Chugai Pharmaceutical Co. Ltd., Biogen Inc., Kyowa Kirin Co. Ltd., Oramed Pharmaceuticals Inc., Sandoz International GmbH, Hualan Biological Engineering Inc., Genentech Inc., ProBiogen AG, Diasome Pharmaceuticals Inc., Generex Biotechnology Corp., GeneScience Pharmaceuticals Co. Ltd.

What Are the Primary Growth Drivers in the Therapeutic Proteins Market?

Technological advancements in the creation of protein-based medicine are propelling the therapeutic proteins market forward. The production of therapeutic proteins is not possible through chemical synthesis, but instead, relies on genetic engineering and recombinant DNA technology within living cells or organisms. The manufacturing, purity, lifespan, aim, and efficacy of therapeutic protein drugs are enhanced by protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX represent therapeutic proteins drugs that have been manufactured utilising protein engineering technologies and granted FDA approval in the last half-decade.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2555&type=smp

What Are the Leading Segments in the Global Therapeutic Proteins Industry?

The therapeutic proteins market covered in this report is segmented –

1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone

2) By Function: Enzymatic And Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics

3) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications

Subsegments:

1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin

2) By Fusion Protein: Tnf-Alpha Inhibitors, Anti-Cd20 Fusion Proteins, Other Targeted Fusion Proteins

3) By Erythropoietin: Epoetin Alpha, Darbepoetin Alfa, Other Erythropoietin Variants

4) By Interferon: Interferon Alpha, Interferon Beta, Interferon Gamma

5) By Human Growth Hormone: Somatropin, Somatrem

6) By Follicle Stimulating Hormone: Follitropin Alpha, Follitropin Beta

What Are the Key Market Trends in the Therapeutic Proteins Industry?

The expansion of biosimilar drugs in the international market will decelerate the growth of the therapeutic proteins market. The termination of patents for therapeutic proteins like monoclonal antibodies paves the way for biosimilars. For example, Amneal Pharmaceuticals, Inc., an American company specializing in generics and specialty pharmaceuticals, introduced ALYMSY (bevacizumab-maly) in the United States in October 2022. These affordable treatment options, similar to original biologics, negatively impact the revenue and sales of the therapeutic proteins market.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

What Is the Regional Outlook for the Therapeutic Proteins Market?

The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2555

This Report Delivers Insight On:

1. How big is the therapeutic proteins market, and how is it changing globally?

2. Who are the major companies in the therapeutic proteins market, and how are they performing?

3. What are the key opportunities and risks in the therapeutic proteins market right now?

4. Which products or customer segments are growing the most in the therapeutic proteins market?

5. What factors are helping or slowing down the growth of the therapeutic proteins market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model